A new study finds a possible association between certain testosterone treatments and the risk for prostate cancer in men, according to a new report.

An article published October 20th in Prostate Cancer News Today notes the findings of research led by a team at the University of Illinois in Chicago, who found that male rats receiving hormone-raising implants and injections may be more likely to develop prostate tumors. After subjects were tested with slow-release and standard testosterone implants, it was discovered that ten to eighteen percent of rats with the slow release implants grew tumors, as did 50 to 71 percent of those with standard implants. Both groups were given the same amount of the carcinogen, N-nitroso-N-methylurea (MNU).

Given the similar outcomes of implanting the rats with slow-release and standard hormone therapies, researchers suggest that extra doses of testosterone do not affect serum levels, and can still cause tumor growth. Findings of the University of Illinois study were released in the journal Endocrinology.

According to Prostate Cancer News Today, the hormone therapy research prompted its authors to explore the safety and effectiveness of testosterone treatments in patients using them for conditions other than hypogonadism, which refers to abnormally-low levels of the hormone in conjunction with a medical illness or injury. Upon the market entrance of these products in the 1950s, they have solely been approved for this use by the U.S. Food and Drug Administration (FDA).

Testim, Axiron and AndroGel Lawsuits Filed in Illinois Federal Court

The University of Illinois researchers’ new angle is particularly relevant to the hundreds of testosterone lawsuits now filed against a number of manufacturers that allege the off-label promotion of AndroGel, Testim and other products for problems not related to hypogonadism. Claimants in these cases accuse several companies of marketing their prescription treatments as a remedy for “Low T,” a condition categorized by low libido, sexual dysfunction, fatigue and other symptoms associated with aging. In September, a panel of expert advisers from the FDA convened to discuss whether such medications should be re-labeled to notify men that they have not been proven effective in treating these issues, and voted 20-1 in favor of new drug packaging.

Hundreds of testosterone lawsuits that sue the makers of AndroGel and other products have been filed in a federal multidistrict litigation (MDL) established in the U.S. District Court, Northern District of Illinois, where they have been centralized for pretrial proceedings.

Contact a Testosterone Lawyer Today

If you were prescribed a testosterone medication to treat symptoms not related to hypogonadism, call our Firm today. You may be eligible to pursue a lawsuit: (877) 779-1414.

Published November 19, 2014 by